I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3896人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088786, encodeId=01c62088e8691, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, objectType=article, longId=188493, objectId=779818849367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779818849367, replyNumber=0, likeNumber=100, createdTime=2020-09-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779818849367, moduleTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779818849367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088825, encodeId=8b9b2088825bc, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=91, createdTime=2021-09-07, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088816, encodeId=88a72088816aa, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验, objectType=article, longId=198325, objectId=726b198325ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=726b198325ff, replyNumber=0, likeNumber=71, createdTime=2020-12-14, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=726b198325ff, moduleTitle=Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=726b198325ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088831, encodeId=864b208883138, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=单抗III期临床试验失败案例及原因分析, objectType=article, longId=201985, objectId=5e8f20198506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e8f20198506, replyNumber=0, likeNumber=84, createdTime=2021-06-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e8f20198506, moduleTitle=单抗III期临床试验失败案例及原因分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e8f20198506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088815, encodeId=6756208881580, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, objectType=article, longId=198175, objectId=65311981e586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65311981e586, replyNumber=0, likeNumber=0, createdTime=2020-11-27, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65311981e586, moduleTitle=IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65311981e586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088783, encodeId=a1d52088e83d4, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, objectType=article, longId=187585, objectId=d55418e58511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55418e58511, replyNumber=0, likeNumber=46, createdTime=2020-04-02, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55418e58511, moduleTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d55418e58511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088793, encodeId=6cf92088e9336, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Losmapimod治疗面肩胛肱型肌营养不良症的I期临床试验取得积极结果, objectType=article, longId=190847, objectId=dcd819084eb8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcd819084eb8, replyNumber=0, likeNumber=83, createdTime=2020-10-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcd819084eb8, moduleTitle=Losmapimod治疗面肩胛肱型肌营养不良症的I期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcd819084eb8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088784, encodeId=f7dc2088e848d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, objectType=article, longId=187590, objectId=c62918e5909e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62918e5909e, replyNumber=0, likeNumber=78, createdTime=2020-06-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62918e5909e, moduleTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62918e5909e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088836, encodeId=9f86208883620, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, objectType=article, longId=202718, objectId=5865202e1851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5865202e1851, replyNumber=0, likeNumber=56, createdTime=2021-01-07, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5865202e1851, moduleTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5865202e1851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088799, encodeId=17a62088e997e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, objectType=article, longId=193033, objectId=b12819303320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12819303320, replyNumber=0, likeNumber=71, createdTime=2020-06-04, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12819303320, moduleTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12819303320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088822, encodeId=586020888226b, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, objectType=article, longId=200591, objectId=c78820059127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78820059127, replyNumber=0, likeNumber=61, createdTime=2021-01-29, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78820059127, moduleTitle=抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c78820059127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088800, encodeId=6fb520888009d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=193035, objectId=ed7619303569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed7619303569, replyNumber=0, likeNumber=67, createdTime=2021-03-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed7619303569, moduleTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7619303569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088841, encodeId=05272088841e9, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, objectType=article, longId=203849, objectId=7f4820384995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f4820384995, replyNumber=0, likeNumber=65, createdTime=2021-08-22, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f4820384995, moduleTitle=FDA批准AMZ002治疗婴儿癫痫病的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f4820384995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088781, encodeId=ae7f2088e8159, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=基因疗法治疗充血性心衰：NAN-101的I期临床试验已开始, objectType=article, longId=187515, objectId=788318e515e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788318e515e0, replyNumber=0, likeNumber=56, createdTime=2020-12-06, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788318e515e0, moduleTitle=基因疗法治疗充血性心衰：NAN-101的I期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=788318e515e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088820, encodeId=b6052088820a6, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, objectType=article, longId=199865, objectId=756f199865ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f199865ac, replyNumber=0, likeNumber=65, createdTime=2021-03-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f199865ac, moduleTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756f199865ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088821, encodeId=cfa9208882109, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, objectType=article, longId=200046, objectId=dd8a2000461b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd8a2000461b, replyNumber=0, likeNumber=53, createdTime=2021-04-01, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd8a2000461b, moduleTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd8a2000461b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088773, encodeId=7d772088e738a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=54, createdTime=2019-12-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088778, encodeId=92d12088e7843, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=口服溃疡性结肠炎新药Brilacidin的I期临床试验, objectType=article, longId=186742, objectId=dc09186e42b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc09186e42b5, replyNumber=0, likeNumber=88, createdTime=2020-04-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc09186e42b5, moduleTitle=口服溃疡性结肠炎新药Brilacidin的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc09186e42b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088830, encodeId=1007208883005, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , objectType=article, longId=201778, objectId=df60201e785f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df60201e785f, replyNumber=0, likeNumber=0, createdTime=2021-04-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df60201e785f, moduleTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df60201e785f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088819, encodeId=ebab20888198a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=大麻素！或是治疗阿尔茨海默症的希望，FDA已批准开展I期临床试验, objectType=article, longId=199297, objectId=c09119929e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c09119929e48, replyNumber=0, likeNumber=80, createdTime=2021-05-27, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c09119929e48, moduleTitle=大麻素！或是治疗阿尔茨海默症的希望，FDA已批准开展I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c09119929e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

脑肿瘤一线治疗：VAL-083的II期临床试验即将开始

2020-09-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2021-09-07

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Asunercept治疗COVID-19：已在欧洲及俄罗斯开展II期临床试验

2020-12-14

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

单抗III期临床试验失败案例及原因分析

2021-06-10

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

IMU-838联合Oseltamivir治疗中重度COVID-19的II期临床试验：首位患者已入组

2020-11-27

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册

2020-04-02

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Losmapimod治疗面肩胛肱型肌营养不良症的I期临床试验取得积极结果

2020-10-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

通用型流感疫苗M-001的II期临床试验取得积极结果

2020-06-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验

2021-01-07

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效

2020-06-04

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

抗COVID-19单克隆抗体候选药物CT-P59：I期临床试验获得积极结果

2021-01-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Merimepodib治疗COVID-19的II期临床试验：即将开始

2021-03-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA批准AMZ002治疗婴儿癫痫病的III期临床试验

2021-08-22

仁者大医 (审核中...)

前往app查看评论内容

#I期临床试验#

基因疗法治疗充血性心衰：NAN-101的I期临床试验已开始

2020-12-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验

2021-03-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验

2021-04-01

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2019-12-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

口服溃疡性结肠炎新药Brilacidin的I期临床试验

2020-04-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？

2021-04-10

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

大麻素！或是治疗阿尔茨海默症的希望，FDA已批准开展I期临床试验

2021-05-27

科室
- - 订阅+
  - 更多科室
工具
服务